News | News By Subject | News by Disease News By Date | Search News

Lung cancer News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AstraZeneca PLC (AZN) Stock Hits 2017 High as Lung Cancer Med Reduces Death Risk in Phase III Study     5/15/2017
Catastrophic Year for Bay Area's OncoMed (OMED) Continues as Lead Drug Comes Crashing Down in Phase II Study     5/9/2017
Takeda (TKPYY)'s $5 Billion Bet on Ariad (ARIA) Pays Off With Accelerated Approval of Lung Cancer Med     5/1/2017
The FDA Calls Pfizer (PFE)’s Next-Generation Lung Cancer Drug a Breakthrough     4/28/2017
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed     4/27/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study     4/18/2017
How This Drug Candidate Could be a Winner in Gilead (GILD)'s Pipeline     3/23/2017
Heat Biologics (HTBX) Rockets as Lung Cancer Med Hits Mid-Stage Goals     3/22/2017
Genentech (RHHBY)'s $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire     2/8/2017
The 7 Worst Clinical Disasters of 2016     12/27/2016
Concordia (CXR.TO) Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index     12/19/2016
Bristol-Myers Squibb (BMY) Looks Over Its Shoulder as Opdivo Disappoints While Merck & Co. (MRK)'s Keytruda Shines in Lung Cancer Study     10/10/2016
Genentech (RHHBY)’s Lung Cancer Drug Alecensa Gets 2nd FDA Breakthrough Status     10/5/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle     9/23/2016
FDA Grants Priority Review and Breakthrough Tag for Merck & Co. (MRK)’s Keytruda     9/7/2016

News from Around the Web
How Did Bristol-Myers Squibb (BMY) Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss     6/5/2017
New Blood Test Could Treat Non-Small-Cell Lung Cancer Faster, The Journal of Molecular Diagnostics Reveals     4/19/2017
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug     2/17/2017
Liquid Biopsy For Lung Cancer Provides Rapid Results At Low Cost And No Trauma, Stanford University Study     1/6/2017
Czech Scientists Develop Human Lung Model To Aid Treatments, Brno University Of Technology Study     11/29/2016
Balance Of Power Shifts With Merck & Co. (MRK)'s Keytruda First-Line Therapy Approval In Lung Cancer     10/26/2016
Genentech (RHHBY)’s Tecentriq Wins Second Approval of the Year, This Time for Lung Cancer     10/19/2016
AI Beats Doctors At Visual Diagnosis, Observes Many Times More Lung Cancer Signals, Stanford University Study     8/19/2016
Transgenomic, Inc. (TBIO) Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer     7/25/2016
University of Louisville Teams Up With Company To Help Lung Cancer Diagnosis     6/15/2016
This Diet Ups Your Lung Cancer Even If You Don't Smoke, MD Anderson Cancer Center Study     3/9/2016
Biotech Startup Yihuo Bio To Produce New Device For Early Detection Of Lung Cancer     2/29/2016
Could A Lung Cancer Drug Work Better With Coke? Erasmus MC Study     2/16/2016
This Lung Cancer Drug May Not Be What It Seems, Chemists Say     1/4/2016
Study Suggests Indi's Xpresys Test Could Reduce Invasive Procedures In NSCLC Diagnosis     12/23/2015

Press Releases
Novartis AG (NVS) Combination Targeted Therapy Tafinlar + Mekinist Receives FDA Approval For BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)     6/23/2017
Novartis AG (NVS) Combination Targeted Therapy Tafinlar + Mekinist Receives FDA Approval For BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)     6/23/2017
FDA Approves Thermo Fisher Scientific (TMO)'s First Companion Diagnostic Test to Screen Multiple Non-Small Cell Lung Cancer Therapies     6/23/2017
GENFIT (ALGFT) Reaches A Critical Milestone Towards The Development Of A Non-Invasive In Vitro Diagnostic (IVD) Test For NASH     6/23/2017
Elekta Release: New Data From The Elekta Lung Research Group Support The Use Of Stereotactic Body Radiation Therapy In Elderly Patients With Early-Stage Lung Cancer     6/15/2017
Questions Rise As Incyte (INCY) Omits Response Rate Data From Several Patients Enrolled In IDO Lung Cancer Study     6/5/2017
ARMO BioSciences Announces Promising Response Rates And Survival Data In Patients With Advanced NSCLC And RCC From Phase I/Ib Trial For Immunotherapy AM0010 With Checkpoint Inhibitors     6/5/2017
CARsgen Therapeutics Presents Phase I Results Of CAR-GPC3 T HCC Trial At ASCO 2017 Annual Meeting     6/5/2017
Phase III Study Showed Genentech (RHHBY)’s Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer     6/5/2017
Peregrine (PPHM) Presents Preliminary Correlative Analysis Of PD-L1 Expression From SUNRISE Trial At ASCO 2017     6/5/2017
Incyte (INCY) Release: Combination Of Epacadostat Plus Keytruda (Pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)     6/5/2017
Longer Term Follow-Up Data With Merck & Co. (MRK)’S KEYTRUDA (Pembrolizumab) In Combination With Pemetrexed And Carboplatin In First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) To Be Presented At 2017 ASCO Annual Meeting     6/5/2017
Corvus Pharma Announces Interim Results Demonstrating Anti-Tumor Activity Of CPI-444 In Renal And Lung Cancer Patients Resistant Or Refractory To Prior PD-(L)1 Treatment     6/5/2017
OxOnc Announces That Co-Development Partner Has Received Approval In Japan And Taiwan For Crizotinib (Xalkori) As A First-Line Treatment For Patients With ROS1-Positive Non-Small Cell Lung Cancer     6/2/2017
Vaxon Biotech SA Announces Results Of Its Phase IIb Lung Cancer Trial Of Vx-001, A Therapeutic Vaccine Based On Optimized Cryptic Peptides     6/1/2017

//-->